User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.

  1. Berntorp, Bull World Health Organ, 73, 691 (1995)
  2. COLLINS P., FARADJI A., MORFINI M., ENRIQUEZ M. M., SCHWARTZ L., Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study, 10.1111/j.1538-7836.2009.03650.x
  3. COLVIN B. T., ASTERMARK J., FISCHER K., GRINGERI A., LASSILA R., SCHRAMM W., THOMAS A., INGERSLEV J., , European principles of haemophilia care, 10.1111/j.1365-2516.2007.01625.x
  4. National Hemophilia Foundation Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf
  5. Richards Michael, Williams Michael, Chalmers Elizabeth, Liesner Ri, Collins Peter, Vidler Vicky, Hanley John, A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A : Guideline, 10.1111/j.1365-2141.2010.08139.x
  6. Srivastava A., Brewer A. K., Mauser-Bunschoten E. P., Key N. S., Kitchen S., Llinas A., Ludlam C. A., Mahlangu J. N., Mulder K., Poon M. C., Street A., , Guidelines for the management of hemophilia, 10.1111/j.1365-2516.2012.02909.x
  7. Berntorp E., Astermark J., Bjorkman S., Blanchette V. S., Fischer K., Giangrande P. L. F., Gringeri A., Ljung R. C., Manco-Johnson M. J., Morfini M., Kilcoyne R. F., Petrini P., Rodriguez-Merchan E. C., Schramm W., Shapiro A., M. Van Den Berg H., Hart C., Consensus perspectives on prophylactic therapy for haemophilia: summary statement, 10.1046/j.1365-2516.9.s1.17.x
  8. Manco-Johnson Marilyn J., Abshire Thomas C., Shapiro Amy D., Riske Brenda, Hacker Michele R., Kilcoyne Ray, Ingram J. David, Manco-Johnson Michael L., Funk Sharon, Jacobson Linda, Valentino Leonard A., Hoots W. Keith, Buchanan George R., DiMichele Donna, Recht Michael, Brown Deborah, Leissinger Cindy, Bleak Shirley, Cohen Alan, Mathew Prasad, Matsunaga Alison, Medeiros Desiree, Nugent Diane, Thomas Gregory A., Thompson Alexis A., McRedmond Kevin, Soucie J. Michael, Austin Harlan, Evatt Bruce L., Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, 10.1056/nejmoa067659
  9. Brackmann, Haemostasis, 22, 251 (1992)
  10. LOFQVIST THOMAS, NILSSON INGA MARIE, BERNTORP ERIK, PETTERSSON HOLGER, Haemophilia prophylaxis in young patients-a long-term follow-up, 10.1046/j.1365-2796.1997.130135000.x
  11. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., KREUZ W., ESCURIOLA-ETTINGSHAUSEN C., FUNK M., SCHMIDT H., KORNHUBER B., When should prophylactic treatment in patients with haemophilia A and B start?- The German experience, 10.1046/j.1365-2516.1998.440413.x
  12. van den Berg H. M., Fischer K., Mauser-Bunschoten E. P., Beek F. J. A., Roosendaal G., van der Bom J. G., Nieuwenhuis H. K., Long-term outcome of individualized prophylactic treatment of children with severe haemophilia, 10.1046/j.1365-2141.2001.02580.x
  13. Aronstam A., Arblaster P. G., Rainsford S. G., Turk P., Slattery M., Alderson M. R., Hall D. E., Kirk P. J., Prophylaxis in Haemophilia: A Double-blind Controlled Trial, 10.1111/j.1365-2141.1976.tb00973.x
  14. Fischer K., Van der Bom J. G., Molho P., Negrier C., Mauser-Bunschoten E. P., Roosendaal G., De Kleijn P., Grobbee D. E., Van Den Berg H. M., Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome, 10.1046/j.1365-2516.2002.00695.x
  15. Manco-Johnson M. J., Kempton C. L., Reding M. T., Lissitchkov T., Goranov S., Gercheva L., Rusen L., Ghinea M., Uscatescu V., Rescia V., Hong W., Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART), 10.1111/jth.12202
  16. VALENTINO L. A., MAMONOV V., HELLMANN A., QUON D. V., CHYBICKA A., SCHROTH P., PATRONE L., WONG W.-Y., , A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management : Comparisons of treatment in hemophilia A management, 10.1111/j.1538-7836.2011.04611.x
  17. ALEDORT L. M., HASCHMEYER R. H., PETTERSSON H., , A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs, 10.1111/j.1365-2796.1994.tb00815.x
  18. GRINGERI A., LUNDIN B., VON MACKENSEN S., MANTOVANI L., MANNUCCI P. M., , A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) : Prophylaxis in hemophilia A, 10.1111/j.1538-7836.2011.04214.x
  19. TAGLIAFERRI A., FRANCHINI M., COPPOLA A., RIVOLTA G. F., SANTORO C., ROSSETTI G., FEOLA G., ZANON E., DRAGANI A., IANNACCARO P., RADOSSI P., MANNUCCI P. M., Effects of secondary prophylaxis started in adolescent and adult haemophiliacs, 10.1111/j.1365-2516.2008.01791.x
  20. DE MOERLOOSE P., URBANCIK W., VAN DEN BERG H. M., RICHARDS M., A survey of adherence to haemophilia therapy in six European countries: results and recommendations, 10.1111/j.1365-2516.2008.01843.x
  21. Hacker M. R., Geraghty S., Manco-Johnson M., Barriers to compliance with prophylaxis therapy in haemophilia, 10.1046/j.1365-2516.2001.00534.x
  22. ZAPPA S., McDANIEL M., MARANDOLA J., ALLEN G., Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey : 2010 PRACTICE PATTERNS SURVEY RESULTS FOR HAEMOPHILIA TREATMENT, 10.1111/j.1365-2516.2012.02770.x
  23. Martinowitz Uri, Windyga Jerzy, Di Minno Giovanni, Hellmann Andrzej, Pabinger Ingrid, Enriquez Monika, Schwartz Lawrence, Ingerslev Jørgen, Powell Jerry, , Efficacy and safety of prophylaxis with once-weekly BAY 79–4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients : A randomised, active-controlled, double-blind study, 10.1160/th12-03-0188
  24. GERAGHTY S., DUNKLEY T., HARRINGTON C., LINDVALL K., MAAHS J., SEK J., Practice patterns in haemophilia A therapy - global progress towards optimal care, 10.1111/j.1365-2516.2006.01189.x
  25. Butler Regina B., McClure Wilma, Wulff Karen, Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States, 10.1046/j.1365-2516.2003.00792.x
  26. NILSSON INGA MARIE, HEDNER ULLA, AHLBERG ÅKE, HAEMOPHILIA PROPHYLAXIS IN SWEDEN, 10.1111/j.1651-2227.1976.tb16525.x
  27. RICHARDS M., ALTISENT C., BATOROVA A., CHAMBOST H., DOLAN G., DE MOERLOOSE P., FRAGA M., HERMANS C., KARAFOULIDOU A., KLAMROTH R., LASSILA R., ROTHSCHILD C., , Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data, 10.1111/j.1365-2516.2007.01478.x
  28. WALSH C. E., VALENTINO L. A., Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices, 10.1111/j.1365-2516.2009.02036.x
  29. Gringeri A., Lambert T., Street A., Aledort L., , Tertiary prophylaxis in adults: is there a rationale?, 10.1111/j.1365-2516.2012.02843.x
Bibliographic reference Lalezari, Shadan ; Coppola, Antonio ; Lin, Jasper ; Enriquez, Monika Maas ; Tseneklidou-Stoeter, Despina ; et. al. Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study.. In: Haemophilia, Vol. 20, no.3, p. 354-361 (2014)
Permanent URL http://hdl.handle.net/2078.1/210696